Juniper (JNP) Alert: Johnson Fistel Investigates Proposed Sale of Juniper Pharmaceuticals, Inc.; Are Shareholders Getting a Fair Deal?
SAN DIEGO, July 3, 2018 /PRNewswire/ -- Shareholder rights law firm Johnson Fistel, LLP has launched an investigation into whether the board members of Juniper Pharmaceuticals, Inc. ("Juniper") (NASDAQ: JNP) breached their fiduciary duties in connection with the proposed sale of the Company to Catalent, Inc. ("Catalent").
On July 3, 2018, Juniper announced that it had signed a definitive merger agreement with Catalent. Under the terms of the transaction, Catalent will acquire all of the outstanding shares of Juniper at a price of $11.50 per share in cash.
The investigation concerns whether the Juniper board failed to satisfy its duties to the Company shareholders, including whether the board adequately pursued alternatives to the acquisition and whether the board obtained the best price possible for Juniper shares of common stock. Nationally recognized Johnson Fistel is investigating whether the proposed deal represents adequate consideration, especially given one Wall Street analyst has a $20.00 price target on the stock.
If you are a shareholder of Juniper and believe the proposed buyout price is too low or you're interested in learning more about the investigation or your legal rights and remedies, please contact lead analyst Jim Baker ([email protected]) at 619-814-4471. If emailing, please include a phone number.
About Johnson Fistel, LLP:
Johnson Fistel, LLP is a nationally recognized shareholder rights law firm with offices in California, New York and Georgia. The firm represents individual and institutional investors in shareholder derivative and securities class action lawsuits. For more information about the firm and its attorneys, please visit http://www.johnsonfistel.com. Attorney advertising. Past results do not guarantee future outcomes.
Contact:
Johnson Fistel, LLP
Jim Baker, 619-814-4471
[email protected]
SOURCE Johnson Fistel, LLP
Share this article